Ovid Therapeutics Inc

(NASDAQ:OVID)

Latest On Ovid Therapeutics Inc (OVID):

Date/Time Type Description Signal Details
2023-05-05 17:24 ESTNewsOvid Therapeutics GAAP EPS of -$0.19 misses by $0.02, revenue of $0.07M beats by $0.05MN/A
2023-05-01 12:38 ESTNewsOvid to invest $10M in Graviton to license neuro disease drug candidateN/A
2023-03-13 17:24 ESTNewsOvid Therapeutics GAAP EPS of -$0.16 beats by $0.02N/A
2022-11-08 17:12 ESTNewsOvid Therapeutics GAAP EPS of -$0.17 beats by $0.04N/A
2022-08-17 22:45 ESTNewsOvid Therapeutics (OVID) Corporate Presentation - SlideshowN/A
2022-08-10 04:11 ESTNewsOvid Therapeutics GAAP EPS of -$0.21 beats by $0.04N/A
2022-05-10 11:35 ESTNewsOvid Therapeutics GAAP EPS of -$0.23 misses by $0.02, revenue of $1.45MN/A
2022-03-16 08:15 ESTNewsOvid Therapeutics GAAP EPS of -$0.38 misses by $0.22N/A
2022-01-03 07:57 ESTNewsOvid Therapeutics inks licensing deal with AstraZeneca in epilepsies and other neuropathic conditionsN/A
2021-11-10 13:37 ESTNewsOvid Therapeutics EPS beats by $0.03N/A
2021-08-16 22:49 ESTNewsOvid Therapeutics EPS misses by $0.06N/A
2021-07-21 19:06 ESTNewsOvid Therapeutics appoints Jeff Rona as CFON/A
2021-07-21 18:55 ESTNewsOvid Therapeutics: Good Entry Point For InvestorsN/A
2021-07-21 18:44 ESTNewsOvid Therapeutics names Jason Tardio Chief Operating OfficerN/A
2021-04-21 04:19 ESTNewsPush for Merck to work with GSK on vaccine, Ovid price target halved, and more in today's analyst action actionN/A
2021-04-20 09:36 ESTNewsOvid Therapeutics dips 3% as Cantor downgrades on pipeline setbacksN/A
2021-03-17 05:41 ESTNewsOvid Therapeutics EPS misses by $0.04, beats on revenueN/A
2021-03-16 21:41 ESTEarnings EstimateAn EPS average of -$0.16 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-16 21:41 ESTEarnings EstimateAn EPS average of -$0.69 is estimated for the 2022 year.Sell
2021-03-08 12:16 ESTAnalyst RatingThe Analyst Target Price has increased from $6 to $6.25.Buy
2021-03-04 06:57 ESTNewsOvid downgraded to sector perform at RBC as shares surge 34% on Takeda dealN/A
2021-03-04 06:57 ESTNewsFUBO, RKT, TRXC and SOS among midday moversN/A
2021-03-03 11:46 ESTNewsOvid shares surge 92% after soticlestat deal with TakedaN/A
2021-01-18 12:17 ESTNewsOvid Therapeutics: Residual Value In OV935 After The OV101 FiascoN/A
2021-01-14 23:42 ESTNewsRevisiting Ovid TherapeuticsN/A
2020-12-04 16:39 ESTAnalyst RatingThe Analyst Target Price has decreased from $10.5 to $6.Neutral
2020-12-03 12:27 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.4 to $10.5.Neutral
2020-12-02 00:59 ESTNewsOvid Therapeutics misses goal in Angelman syndrome treatmentN/A
2020-11-26 21:08 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:01 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 12:57 ESTEarnings EstimateAn EPS average of -$0.39 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-13 06:17 ESTNewsOvid Therapeutics EPS beats by $0.14, beats on revenueN/A
2020-11-08 00:29 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:45 ESTFinancialsCompany financials have been released.Neutral
2020-09-30 13:24 ESTNewsOvid's soticlestat shows positive effect in rare epilepsiesN/A
2020-09-26 13:40 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:46 ESTFinancialsCompany financials have been released.Neutral
2020-09-01 21:42 ESTInsider TradeJEREMY M LEVIN has directly acquired 8,488 shares and currently holds 5,792,530 shares.Buy
2020-08-29 07:52 ESTNewsOvid Therapeutics: Strong Buy After Fall On Necessary Dilution Backed By Positive DataN/A
2020-08-27 09:20 ESTAnalyst RatingThe Analyst Target Price has increased from $14.2 to $14.4.Buy
2020-08-26 13:26 ESTAnalyst RatingThe Analyst Target Price has increased from $13.6 to $14.2.Buy
2020-08-25 16:38 ESTNewsOvid's soticlestat successful in mid-stage study in severe forms of childhood epilepsyN/A
2020-08-25 16:38 ESTNewsOvid prices $50M stock offering at $8 per shareN/A
2020-08-14 09:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 05:33 ESTFinancialsCompany financials have been released.Neutral
2020-08-12 05:32 ESTFinancialsCompany financials have been released.Neutral
2020-08-10 19:27 ESTNewsOvid Therapeutics EPS misses by $0.05N/A
2020-08-06 13:29 ESTFinancialsCompany financials have been released.Neutral
2020-08-05 21:08 ESTNewsOvid Therapeutics Is Quickly Approaching A Transformational Valuation MilestoneN/A
2020-07-31 01:57 ESTFinancialsCompany financials have been released.Neutral

About Ovid Therapeutics Inc (OVID):

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was incorporated in 2014 and is headquartered in New York, New York.

OVID Quotes by TradingView

See Advanced Chart

General

  • Name Ovid Therapeutics Inc
  • Symbol OVID
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 67
  • Fiscal Year EndDecember
  • IPO Date2017-05-05
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.ovidrx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 23.36
  • Price/Book (Most Recent Quarter) 2.94
  • Enterprise Value Revenue 14.5
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Current Year EPS Estimate $0.79
  • Next Year EPS Estimate -$0.69
  • Next Quarter EPS Estimate -$0.39
  • Operating Margin -645%
  • Return on Assets -65%
  • Return on Equity -143%
  • Revenue 12.62 million
  • Earnings Per Share -$1.78
  • Revenue Per Share $0.22
  • Gross Profit 12.62 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 296.88 million
  • EBITDA -53432092
  • PE Ratio -4.19
  • Analyst Target Price $6.25
  • Book Value Per Share $0.66
View More

Share Statistics

  • Shares Outstanding 65.75 million
  • Shares Float 33.47 million
  • % Held by Insiders 3469%
  • % Held by Institutions 39.8%
  • Shares Short 3.22 million
  • Shares Short Prior Month 2.75 million
  • Short Ratio 1.23
  • Short % of Float 6%
  • Short % of Shares Outstanding 5%
View More

Technicals

  • Beta 1.8
  • 52 Week High $8.37
  • 52 Week Low $2.17
  • 50 Day Moving Average 3.47
  • 200 Day Moving Average 4.31
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Ovid Therapeutics Inc (OVID) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Ovid Therapeutics Inc (OVID) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-15-$0.34-$0.31-9.68%
2020-09-302020-11-12$6.91 million-$0.28-$0.3519.35%
2020-06-302020-08-10$N/A-$0.41-$0.35-15.75%
2020-03-312020-05-07$N/A-$0.37-$0.32-15.59%
2019-12-312020-03-11$N/A-$0.35-$0.3911.26%
2019-09-302019-11-08$N/A-$0.43-$0.36-19.48%
2019-06-302019-08-07$N/A-$0.34-$0.4015.59%
2019-03-312019-05-07$N/A-$0.46-$0.41-13.08%
2018-12-312019-03-07$N/A-$0.52-$0.554.59%
2018-09-302018-11-08$N/A-$0.53-$0.6112.61%
2018-06-302018-08-09$N/A-$0.53-$0.6113.1%
2018-03-312018-05-08$N/A-$0.54-$0.53-2.82%
2017-12-312018-03-29$N/A-$0.45-$0.41-9.01%
2017-09-302017-11-09$N/A-$0.38-$0.5430.01%
2017-06-302017-08-10$N/A-$0.57-$0.48-17.82%
2017-03-312017-06-13$N/A-$1.75-$1.802.78%

Ovid Therapeutics Inc (OVID) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development 15.88 million N/A N/A 12.11 million 11.6 million
Income Before Tax -16.42 million N/A N/A -16.97 million -16.63 million
Selling General Administrative 7.44 million N/A N/A 5.16 million 5.17 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -16.32 million N/A N/A -17.27 million -16.77 million
Operating Income -16.4 million N/A N/A -17.27 million -16.77 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue 6.91 million N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net -21127 N/A N/A 298720 131164
Net Income From Continuing Operations -16.42 million N/A N/A -16.97 million -16.63 million
Net Income Applicable to Common Shares -16.42 million -22.55 million -20.03 million -16.97 million -16.63 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -38305 N/A N/A N/A N/A
Change to Liabilities 11.35 million 603509 N/A N/A 3.16 million
Total Cash Flow from Investing Activities -38305 30.94 million N/A N/A -18581
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 47.12 million N/A N/A N/A 58791
Change to Operating Activities 914871 3.19 million N/A N/A 2.74 million
Change in Cash 45.61 million N/A N/A N/A -9.45 million
Total Cash from Operating Activities -1.47 million -17.19 million N/A N/A -9.49 million
Depreciation 78918 N/A N/A N/A 55404
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities -69628 8368 N/A N/A N/A
Change to Net Income 2.61 million 1.49 million N/A N/A 1.18 million
Capital Expenditures 41305 N/A N/A N/A 18211
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities 27.96 million N/A N/A N/A 10.65 million
Total Stockholder Equity 63.64 million N/A N/A 30.05 million 30.05 million
Other Current Liabilities 3.38 million N/A N/A N/A 337773
Total Assets 91.6 million N/A N/A N/A 40.69 million
Common Stock 63435 57082 N/A N/A 37467
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -272.16 million -255.74 million N/A N/A -196.19 million
Other Liabilities 10 million 286562 N/A N/A 286562
Other Assets 753422 752881 N/A N/A 1.47 million
Cash 86.87 million N/A N/A N/A 37.91 million
Total Current Liabilities 17.96 million N/A N/A N/A 10.36 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 137799 115989 N/A N/A 72241
Total Current Assets 90.35 million N/A N/A N/A 39.15 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 63.28 million 30.11 million N/A 29.7 million 30.05 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 3.16 million N/A N/A N/A 5.34 million

Ovid Therapeutics Inc (OVID) Chart:

Ovid Therapeutics Inc (OVID) News:

Below you will find a list of latest news for Ovid Therapeutics Inc (OVID) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Ovid Therapeutics Inc (OVID) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50.8CALL0 22210.97TRUE00
2024-05-1750.05CALL0 670FALSE00
2024-05-177.50CALL0 00FALSE00
2024-05-172.50.01PUT1 459.79FALSE0.010
2024-05-1750PUT0 0168.81TRUE00
2024-05-177.50PUT0 0348.62TRUE00
2024-06-212.50CALL0 0131.81TRUE00
2024-06-2150.04CALL0 600FALSE00
2024-06-217.50CALL0 00FALSE00
2024-06-212.50PUT0 089.26FALSE00
2024-06-2150PUT0 0148.18TRUE00
2024-06-217.50PUT0 0296.34TRUE00
2024-07-192.50.75CALL0 2283.84TRUE00
2024-07-1950.1CALL0 810FALSE00
2024-07-197.50.1CALL0 1870FALSE00
2024-07-192.50.2PUT0 773.37FALSE00
2024-07-1951.9PUT0 2107.63TRUE00
2024-07-197.50PUT0 0189.98TRUE00
2024-10-182.50.9CALL0 3674.11TRUE00
2024-10-1850.15CALL0 4070.23FALSE00
2024-10-187.50.15CALL0 20FALSE00
2024-10-182.50PUT0 056.28FALSE00
2024-10-1851.85PUT0 1582.86TRUE00
2024-10-187.50PUT0 0107.73TRUE00
2025-01-172.51.03CALL0 260.81TRUE00
2025-01-1750.3CALL0 2569.82FALSE00
2025-01-177.50CALL0 088.55FALSE00
2025-01-172.50PUT0 096.27FALSE00
2025-01-1750PUT0 076.1TRUE00
2025-01-177.50PUT0 0166.65TRUE00

Latest OVID Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST415$1.835
Jun 13, 2022 7:54 PM EST38$1.84
Jun 13, 2022 7:58 PM EST100$1.835
Jun 13, 2022 7:58 PM EST120$1.83
Jun 13, 2022 7:59 PM EST196$1.825

Ovid Therapeutics Inc (OVID) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120038475/0001209191-20-038475-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000021545719006576/0000215457-19-006576-index.htm
2019-03-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000021545719007595/0000215457-19-007595-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000031506619001254/0000315066-19-001254-index.htm
2018-12-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000091957418007922/0000919574-18-007922-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000091957420001524/0000919574-20-001524-index.htm
2019-03-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000092189519000644/0000921895-19-000644-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000092189520000516/0000921895-20-000516-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000108514620000790/0001085146-20-000790-index.htm
2019-01-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000117031619000001/0001170316-19-000001-index.htm
2020-01-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000117031620000002/0001170316-20-000002-index.htm
2020-03-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000117031620000003/0001170316-20-000003-index.htm
2018-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000119312518266252/0001193125-18-266252-index.htm
2019-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000119312519044203/0001193125-19-044203-index.htm
2019-02-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636651/000119312519044207/0001193125-19-044207-index.htm
2019-02-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636651/000119312519044216/0001193125-19-044216-index.htm
2019-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000119312519047109/0001193125-19-047109-index.htm
2019-02-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636651/000119312519047374/0001193125-19-047374-index.htm
2019-02-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636651/000119312519047382/0001193125-19-047382-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1636651/000119312519215523/0001193125-19-215523-index.htm
2019-09-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000119312519248745/0001193125-19-248745-index.htm
2019-10-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636651/000119312519261644/0001193125-19-261644-index.htm
2019-10-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636651/000119312519261653/0001193125-19-261653-index.htm
2019-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000119312519263976/0001193125-19-263976-index.htm
2019-10-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636651/000119312519263977/0001193125-19-263977-index.htm
2019-10-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636651/000119312519263978/0001193125-19-263978-index.htm
2019-11-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636651/000119312519289308/0001193125-19-289308-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000119312520036944/0001193125-20-036944-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000119312520036949/0001193125-20-036949-index.htm
2020-03-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1636651/000119312520070452/0001193125-20-070452-index.htm
2020-08-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636651/000119312520231241/0001193125-20-231241-index.htm
2020-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000119312520231250/0001193125-20-231250-index.htm
2019-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119013904/0001209191-19-013904-index.htm
2019-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119013905/0001209191-19-013905-index.htm
2019-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119013906/0001209191-19-013906-index.htm
2019-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119013907/0001209191-19-013907-index.htm
2019-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119013908/0001209191-19-013908-index.htm
2019-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119013909/0001209191-19-013909-index.htm
2019-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119014804/0001209191-19-014804-index.htm
2019-03-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119021381/0001209191-19-021381-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119023196/0001209191-19-023196-index.htm
2019-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119023200/0001209191-19-023200-index.htm
2019-04-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119024055/0001209191-19-024055-index.htm
2019-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119035784/0001209191-19-035784-index.htm
2019-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119035786/0001209191-19-035786-index.htm
2019-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119035795/0001209191-19-035795-index.htm
2019-08-014/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119044045/0001209191-19-044045-index.htm
2019-08-014/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119044050/0001209191-19-044050-index.htm
2019-08-014/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119044055/0001209191-19-044055-index.htm
2019-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119044363/0001209191-19-044363-index.htm
2019-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119052988/0001209191-19-052988-index.htm
2019-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119055000/0001209191-19-055000-index.htm
2019-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119055002/0001209191-19-055002-index.htm
2019-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119056735/0001209191-19-056735-index.htm
2019-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119056741/0001209191-19-056741-index.htm
2019-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119056745/0001209191-19-056745-index.htm
2019-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119056750/0001209191-19-056750-index.htm
2019-11-213Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119057556/0001209191-19-057556-index.htm
2019-11-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119057557/0001209191-19-057557-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119061538/0001209191-19-061538-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119061544/0001209191-19-061544-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119061548/0001209191-19-061548-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119061560/0001209191-19-061560-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919119061568/0001209191-19-061568-index.htm
2020-01-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120000452/0001209191-20-000452-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120035038/0001209191-20-035038-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120035039/0001209191-20-035039-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120035040/0001209191-20-035040-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120035041/0001209191-20-035041-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120038475/0001209191-20-038475-index.htm
2020-09-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120049011/0001209191-20-049011-index.htm
2020-10-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120053404/0001209191-20-053404-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120053411/0001209191-20-053411-index.htm
2020-10-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120054642/0001209191-20-054642-index.htm
2020-10-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120054645/0001209191-20-054645-index.htm
2020-10-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000120919120054653/0001209191-20-054653-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000138713119001273/0001387131-19-001273-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000138713119001275/0001387131-19-001275-index.htm
2019-11-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000139506419000080/0001395064-19-000080-index.htm
2019-11-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000139506419000081/0001395064-19-000081-index.htm
2019-11-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636651/000139506419000082/0001395064-19-000082-index.htm
2019-11-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636651/000139506419000083/0001395064-19-000083-index.htm
2018-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459018023736/0001564590-18-023736-index.htm
2018-10-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459018025039/0001564590-18-025039-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459018028283/0001564590-18-028283-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1636651/000156459018028299/0001564590-18-028299-index.htm
2018-12-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459018030546/0001564590-18-030546-index.htm
2018-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459018030969/0001564590-18-030969-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019000137/0001564590-19-000137-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019000256/0001564590-19-000256-index.htm
2019-03-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019005587/0001564590-19-005587-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019006790/0001564590-19-006790-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1636651/000156459019006804/0001564590-19-006804-index.htm
2019-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019007149/0001564590-19-007149-index.htm
2019-03-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019008718/0001564590-19-008718-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019009688/0001564590-19-009688-index.htm
2019-03-288-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019009737/0001564590-19-009737-index.htm
2019-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1636651/000156459019012763/0001564590-19-012763-index.htm
2019-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1636651/000156459019012766/0001564590-19-012766-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019016217/0001564590-19-016217-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1636651/000156459019016562/0001564590-19-016562-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019019477/0001564590-19-019477-index.htm
2019-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019022139/0001564590-19-022139-index.htm
2019-06-178-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019022662/0001564590-19-022662-index.htm
2019-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019022718/0001564590-19-022718-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019023666/0001564590-19-023666-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019023703/0001564590-19-023703-index.htm
2019-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019024285/0001564590-19-024285-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019030143/0001564590-19-030143-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1636651/000156459019030178/0001564590-19-030178-index.htm
2019-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019034294/0001564590-19-034294-index.htm
2019-09-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019034545/0001564590-19-034545-index.htm
2019-09-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019035162/0001564590-19-035162-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019035235/0001564590-19-035235-index.htm
2019-11-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019039281/0001564590-19-039281-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019042022/0001564590-19-042022-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1636651/000156459019042028/0001564590-19-042028-index.htm
2019-12-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459019046730/0001564590-19-046730-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020000319/0001564590-20-000319-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020008128/0001564590-20-008128-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020009878/0001564590-20-009878-index.htm
2020-03-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1636651/000156459020010108/0001564590-20-010108-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020010659/0001564590-20-010659-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020013857/0001564590-20-013857-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1636651/000156459020018268/0001564590-20-018268-index.htm
2020-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1636651/000156459020018286/0001564590-20-018286-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020022392/0001564590-20-022392-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1636651/000156459020023002/0001564590-20-023002-index.htm
2020-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020028515/0001564590-20-028515-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020029613/0001564590-20-029613-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020029856/0001564590-20-029856-index.htm
2020-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020032209/0001564590-20-032209-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020038634/0001564590-20-038634-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1636651/000156459020038644/0001564590-20-038644-index.htm
2020-08-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020041092/0001564590-20-041092-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020045189/0001564590-20-045189-index.htm
2020-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636651/000156459020047230/0001564590-20-047230-index.htm
2019-03-01SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636651/000176882419000004/0001768824-19-000004-index.htm
2019-10-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636651/000176882419000006/0001768824-19-000006-index.htm
2019-11-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636651/000176882419000008/0001768824-19-000008-index.htm
2020-05-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636651/000176882420000001/0001768824-20-000001-index.htm
2020-05-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636651/000176882420000003/0001768824-20-000003-index.htm

Ovid Therapeutics Inc (OVID) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ovid Therapeutics Inc (OVID). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3469%
Institutional Ownership: 3980%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-02-26Karen BernsteinDirectorBuy10,000.002.0220,210.0020,000.00https://www.sec.gov/Archives/edgar/data/1636651/000120919119014804/0001209191-19-014804-index.htm
2019-02-22JEREMY M LEVINCEOBuy75,000.002.00150,000.004,676,529.00https://www.sec.gov/Archives/edgar/data/1636651/000120919119013905/0001209191-19-013905-index.htm
2019-10-08JEREMY M LEVINCEOBuy60,000.002.50150,000.004,736,529.00https://www.sec.gov/Archives/edgar/data/1636651/000120919119052988/0001209191-19-052988-index.htm
2019-10-08PHARMACEUTICAL CO LTD TAKEDA10% Share HolderBuy2,000,000.002.505,000,000.005,750,000.00https://www.sec.gov/Archives/edgar/data/1636651/000139506419000083/0001395064-19-000083-index.htm
2020-08-28JEREMY M LEVINCEOBuy8,488.005.8449,569.925,792,530.00https://www.sec.gov/Archives/edgar/data/1636651/000120919120049011/0001209191-20-049011-index.htm